Epidemiológiai felmérések szerint az 1-es típusú diabetes incidenciája és prevalenciája világszerte növekvőben van. Az incidencia elsősorban csecsemő- és kisdedkorban emelkedett. Az 1a típusú autoimmun diabetes predikciója a pozitív családi anamnézis vagy a genetikai, immunológiai és metabolikus markerek segítségével lehetséges. A betegség prevenciója a patogenezis három szintjén valósítható meg: primer prevenció azon egyedekben, akikben a béta-sejt-pusztulás még nem észlelhető, szekunder prevenció a már béta-sejt-pusztulás jeleit mutatókban, és tercier prevenció az újonnan diagnosztizált 1-es típusú diabeteses betegekben. Az utóbbi években ismereteink a betegség patogeneziséről gyorsan gyarapodtak és világszerte számos prevenciós klinikai vizsgálatot indítottak. Feltehetőleg az immunintervenció bizonyul majd a leghatásosabbnak az 1-es típusú diabetes megelőzésében. Orv. Hetil., 2011, 152, 1916–1921.
Madácsy L.: A gyermekkori diabetes mellitus. In: Diabetes mellitus. Elmélet és klinikum. (Szerk.: Halmos T., Jermendy G.) Medicina Könyvkiadó, Budapest, 2002, 633–641.
Madácsy L. , '', in Diabetes mellitus. Elmélet és klinikum , (2002 ) -.
Soltész, G., Madácsy, L., Békefi, D. és mtsa: Rising incidence of type 1 diabetes in Hungarian children (1978–1987). Diabet. Med., 1990, 7, 111–114.
Békefi D. , 'Rising incidence of type 1 diabetes in Hungarian children (1978–1987) ' (1990 ) 7 Diabet. Med. : 111 -114 .
Gyürüs, É., Green, A., Soltész, G. és mtsai: Dynamic changes in the trends in incidence of type 1 diabetes in children in Hungary (1978–98). Pediatr. Diabetes, 2002, 3, 194–199.
Soltész G. , 'Dynamic changes in the trends in incidence of type 1 diabetes in children in Hungary (1978–98) ' (2002 ) 3 Pediatr. Diabetes : 194 -199 .
Skyler, J. S., Marks, J. B.: Immune intervention in type 1 diabetes mellitus. Diabetes Reviews, 1993, 1, 15–42.
Marks J. B. , 'Immune intervention in type 1 diabetes mellitus ' (1993 ) 1 Diabetes Reviews : 15 -42 .
American Diabetes Association ad hoc Expert Committee: Prevention of type 1 diabetes mellitus. Diabetes, 1990, 39, 1151–1152.
'Prevention of type 1 diabetes mellitus ' (1990 ) 39 Diabetes : 1151 -1152 .
Zhang, L., Eisenbarth, G. S.: Prediction and prevention of type 1 diabetes mellitus. J. Diabetes, 2011, 3, 48–57.
Eisenbarth G. S. , 'Prediction and prevention of type 1 diabetes mellitus ' (2011 ) 3 J. Diabetes : 48 -57 .
Lukács K., Herman R.: Az 1-es típusú diabétesz genetikai háttere, pathogenesise és a legújabb prevenciós kutatások státusza. Gyermekgyógyászati Továbbképző Szemle, 2007, 12, 51–62.
Herman R. , 'Az 1-es típusú diabétesz genetikai háttere, pathogenesise és a legújabb prevenciós kutatások státusza ' (2007 ) 12 Gyermekgyógyászati Továbbképző Szemle : 51 -62 .
Knip, M.: Prediction and prevention of type 1 diabetes. Acta Paediatr. Suppl., 1998, 425, 54–62.
Knip M. , 'Prediction and prevention of type 1 diabetes ' (1998 ) 425 Acta Paediatr. Suppl. : 54 -62 .
Wherett, D. K., Daneman, D.: Prevention of type 1 diabetes. Endocrinol. Metab. Clin. North Am., 2009, 38, 777–790.
Daneman D. , 'Prevention of type 1 diabetes ' (2009 ) 38 Endocrinol. Metab. Clin. North Am. : 777 -790 .
Thrower, S. L., Bingley, P. J.: Prevention of type 1 diabetes. Br. Med. Bull., 2011, 99, 73–88.
Bingley P. J. , 'Prevention of type 1 diabetes ' (2011 ) 99 Br. Med. Bull. : 73 -88 .
Wenzlau, J. M., Juhl, K., Yu, L. és mtsai: The caution efflux transporter ZnT8 is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 17040–17045.
Yu L. , 'The caution efflux transporter ZnT8 is a major autoantigen in human type 1 diabetes ' (2007 ) 104 Proc. Natl. Acad. Sci. U.S.A. : 17040 -17045 .
Madácsy L.: Az 1-es típusú diabetes mellitus prevenciója. In: Diabetes mellitus. Elmélet és klinikum. (Szerk.: Halmos T., Jermendy G.) Medicina Könyvkiadó, Budapest, 2002, 731–738.
Madácsy L. , '', in Diabetes mellitus. Elmélet és klinikum , (2002 ) -.
Cernea, S., Dobreanu, M., Raz, I.: Prevention of type 1 diabetes: today and tomorrow. Diabetes Metab. Res. Rev., 2010, 26, 602–605.
Raz I. , 'Prevention of type 1 diabetes: today and tomorrow ' (2010 ) 26 Diabetes Metab. Res. Rev. : 602 -605 .
Akerblom, H. K., Virtanen, S. M., Ilonen, J. és mtsai: Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes. Diabetologia, 2005, 48, 829–837.
Ilonen J. , 'Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes ' (2005 ) 48 Diabetologia : 829 -837 .
Bortell, R., Pino, S. C., Greiner, D. L. és mtsai: Closing the circle between the bedside and the banch: Toll-like receptors in models of virally induced diabetes. Ann. N.Y. Acad. Sci., 2008, 1150, 112–122.
Greiner D. L. , 'Closing the circle between the bedside and the banch: Toll-like receptors in models of virally induced diabetes ' (2008 ) 1150 Ann. N.Y. Acad. Sci. : 112 -122 .
Akerblom, H. K., Vaarala, O., Hyöty, H. és mtsai: Environmental factors in the etiology of type 1 diabetes. Am. J. Med. Genet., 2002, 115, 18–29.
Hyöty H. , 'Environmental factors in the etiology of type 1 diabetes ' (2002 ) 115 Am. J. Med. Genet. : 18 -29 .
Badenhoop, K.: Solar power to prevent type 1 diabetes? Pediatr. Diabetes, 2008, 9, 79–80.
Badenhoop K. , 'Solar power to prevent type 1 diabetes? ' (2008 ) 9 Pediatr. Diabetes : 79 -80 .
Virtanen, S. M., Knip, M.: Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age. Am. J. Clin. Nutr., 2003, 78, 1053–1067.
Knip M. , 'Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age ' (2003 ) 78 Am. J. Clin. Nutr. : 1053 -1067 .
Sloka, S., Grant, M., Newhook, L. A: Time series analysis of ultraviolet B radiation and type 1 diabetes in New Fundland. Pediatric Diabetes, 2008, 9, 81–86.
Newhook L. A , 'Time series analysis of ultraviolet B radiation and type 1 diabetes in New Fundland ' (2008 ) 9 Pediatric Diabetes : 81 -86 .
Wicklow, B. A., Taback, S. P.: Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann. N. Y. Acad. Sci., 2006, 1079, 310–312.
Taback S. P. , 'Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk ' (2006 ) 1079 Ann. N. Y. Acad. Sci. : 310 -312 .
Knip, M.: Személyes közlés. 2008.
Elliott, R. B., Chase, H. P.: Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia, 1991, 34, 362–365.
Chase H. P. , 'Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide ' (1991 ) 34 Diabetologia : 362 -365 .
The European Nicotinamide Intervention Trial (ENDIT) Group: Intervening before the onset of type 1 diabetes: baseline data of the European Nicotinamide Intervention Trial (ENDIT). Diabetologia, 2003, 46, 339–346.
'Intervening before the onset of type 1 diabetes: baseline data of the European Nicotinamide Intervention Trial (ENDIT) ' (2003 ) 46 Diabetologia : 339 -346 .
The European Nicotinamide Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet, 2004, 363, 925–931.
'A randomised controlled trial of intervention before the onset of type 1 diabetes ' (2004 ) 363 Lancet : 925 -931 .
Skyler, J. S., Marks, J. B.: Immune intervention in type I diabetes mellitus. Diabetes Rev., 1993, 1, 15–42.
Marks J. B. , 'Immune intervention in type I diabetes mellitus ' (1993 ) 1 Diabetes Rev. : 15 -42 .
Fuchtenbusch, M., Rabl, W., Grassl, B. és mtsai: Delay of type I diabetes in high risk first degree relatives by parenteral antigen administration. Diabetologia, 1998, 41, 536–541.
Grassl B. , 'Delay of type I diabetes in high risk first degree relatives by parenteral antigen administration ' (1998 ) 41 Diabetologia : 536 -541 .
DPT-1 Group: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med., 2002, 346, 1685–1691.
'Effects of insulin in relatives of patients with type 1 diabetes mellitus ' (2002 ) 346 N. Engl. J. Med. : 1685 -1691 .
Skyler, J. S., Krischer, J. P., Wolfsdorf, J. és mtsai: Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial – Type 1. Diabetes Care, 2005, 28, 1068–1076.
Wolfsdorf J. , 'Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial – Type 1 ' (2005 ) 28 Diabetes Care : 1068 -1076 .
Harrison, L. C., Honeyman, M. C., Steele, C. E. és mtsai: Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care, 2004, 27, 2348–2355.
Steele C. E. , 'Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes ' (2004 ) 27 Diabetes Care : 2348 -2355 .
Nanto-Salonen, K., Kupila, A., Simell, S. és mtsai: Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring risk of disease: a double-blind, randomised controlled trial. Lancet, 2008, 372, 1746–1755.
Simell S. , 'Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring risk of disease: a double-blind, randomised controlled trial ' (2008 ) 372 Lancet : 1746 -1755 .
Chatenoud, L.: Les anticorps monoclonaux anti-CD3: une premiere etape vers un traitement du diabete insulino-dependant d’origine auto-immune. Med. Sci. (Paris), 2006, 22, 5–6.
Chatenoud L. , 'Les anticorps monoclonaux anti-CD3: une premiere etape vers un traitement du diabete insulino-dependant d’origine auto-immune ' (2006 ) 22 Med. Sci. (Paris) : 5 -6 .
Raz, I., Elias, D., Avron, A. és mtsai: Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II. Trial. Lancet, 2001, 358, 1749–1753.
Avron A. , 'Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II. Trial ' (2001 ) 358 Lancet : 1749 -1753 .
Schloot, N., Meierhoff, G., Lengyel, C. és mtsai: Effect of heat-shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent onset diabetes mellitus type 1. Diabetes Metab. Res. Rev., 2007, 23, 276–285.
Lengyel C. , 'Effect of heat-shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent onset diabetes mellitus type 1 ' (2007 ) 23 Diabetes Metab. Res. Rev. : 276 -285 .
Chatenaud, L., Bluestone, J.: CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol., 2007, 7, 622–632.
Bluestone J. , 'CD3-specific antibodies: a portal to the treatment of autoimmunity ' (2007 ) 7 Nat. Rev. Immunol. : 622 -632 .
Herold, K. C., Gitelman, S. E., Masharani, U. és mtsai: A single course of anti-CD3 monoclonal antibody OKT3 results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes, 2005, 554, 1753–1769.
Masharani U. , 'A single course of anti-CD3 monoclonal antibody OKT3 results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes ' (2005 ) 554 Diabetes : 1753 -1769 .
Herold, K. C., Gitelman, S. E., Greenbaum, C.: Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol., 2009, 132, 166–173.
Greenbaum C. , 'Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years ' (2009 ) 132 Clin. Immunol. : 166 -173 .
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H. és mtsai: Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta cell function. N. Engl. J. Med., 2009, 361, 2143–2152.
Krause-Steinrauf H. , 'Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta cell function ' (2009 ) 361 N. Engl. J. Med. : 2143 -2152 .
Orban, T., Farkas, K., Jalahej, H. és mtsai: Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J. Autoimmun., 2010, 34, 408–415.
Jalahej H. , 'Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy ' (2010 ) 34 J. Autoimmun. : 408 -415 .
Orbán T.: Személyes közlés. 2010.